Thymoma‐associated myasthenia gravis : Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma
| Autor: | Loredana Petrucci, Marco Lucchi, Melania Guida, Laura Baglietto, Marco Fornili, Antonio Chella, Michelangelo Maestri Tassoni, Anna De Rosa, Franca Melfi, Roberta Ricciardi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine medicine.medical_specialty Thymoma medicine.medical_treatment Antiacetylcholine receptor antibody Gastroenterology 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans Receptors Cholinergic Stage (cooking) Retrospective Studies myasthenia gravis Proportional hazards model business.industry thymoma thymoma recurrence Autoantibody Original Articles General Medicine Middle Aged medicine.disease Primary tumor Myasthenia gravis Thymectomy 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cohort Original Article Female Neoplasm Recurrence Local business |
| Zdroj: | Thoracic Cancer |
| ISSN: | 1759-7714 1759-7706 |
| Popis: | Background Thymoma‐associated myasthenia gravis (TAMG) is one of the subtypes of myasthenia gravis with autoantibodies against the acetylcholine receptor (AChR‐Ab). We analyzed the clinical features of our cohort of TAMG patients and the changes in AChR‐Ab titer before and after thymectomy in order to identify factors predicting thymoma relapses. Methods We retrospectively assessed: age of MG onset, MG clinical status according to MGFA (Myasthenia Gravis Foundation of America), epoch of thymectomy, post‐thymectomy status, oncological features and surgical approach. AChR‐Ab dosages were measured both before and after thymectomy. Linear regression models were applied to identify clinical determinants of AChR‐Ab titers and the Cox regression model was fitted to estimate the factors associated with the risk of thymoma recurrence. Results The study sample included 239 MG patients, 27 of whom experienced one or more recurrences (median follow‐up time: 4.8 years). The AChR‐Ab titers decreased after first thymectomy (P In our paper, we retrospectively analyzed the changes in antiacetylcholine receptor antibody (AChR‐Ab) titer before and after thymectomy and the clinical features of thymoma‐associated myasthenia gravis (TAMG) patients in order to identify clinical and serological predictors of thymoma recurrence. Our study emphasizes the importance of a multidisciplinary approach among Neurologists, Oncologists and Thoracic Surgeons, and identifies subgroups of MG patients with high risk of thymoma recurrence who therefore need a more accurate follow‐up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text